Literature DB >> 7669463

Effect of ketorolac, bupivacaine and low-dose heparin on thrombelastographic variables in vitro.

N M Gibbs1, J W Sear.   

Abstract

We have studied the effects of ketorolac, bupivacaine and low-dose heparin on three thrombelastographic (TEG) variables (r, alpha, MA) in vitro. Blood samples were obtained from 12 healthy volunteers and 88 ASA I-II elective surgical patients. Clinically relevant concentrations of ketorolac (4.1 micrograms ml-1) and bupivacaine (2.7 micrograms ml-1) had little or no effect on the TEG variables. However, low concentrations of heparin (0.07-0.28 u. ml-1) had marked effects on all three TEG variables. Thus the interpretation of TEG abnormalities during anaesthesia and surgery may be confounded by the presence of heparin, but not by clinical concentrations of ketorolac or bupivacaine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7669463     DOI: 10.1093/bja/75.1.27

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  4 in total

1.  Tonsillectomies, ketorolac, and the march of progress.

Authors:  S C Hall
Journal:  Can J Anaesth       Date:  1996-06       Impact factor: 5.063

Review 2.  Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management.

Authors:  J C Gillis; R N Brogden
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

Review 3.  Ketorolac for postoperative pain management in children.

Authors:  J B Forrest; E L Heitlinger; S Revell
Journal:  Drug Saf       Date:  1997-05       Impact factor: 5.606

4.  Thrombodynamics-A new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment.

Authors:  Anna N Balandina; Ilya I Serebriyskiy; Alexander V Poletaev; Dmitry M Polokhov; Marina A Gracheva; Ekaterina M Koltsova; David M Vardanyan; Irina A Taranenko; Alexey Yu Krylov; Evdokiya S Urnova; Kirill V Lobastov; Artem V Chernyakov; Elena M Shulutko; Andrey P Momot; Alexander M Shulutko; Fazoil I Ataullakhanov
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.